Oslo, 7 June 2021 - The Board of Directors of EXACT Therapeutics AS (the
"Company") has resolved on June 4th 2021 to increase the share capital of the
Company by NOK 97.668 through the issuance of 24,427 new shares.
The new shares are issued pursuant to the authorisation provided to the Board of
Directors at the Annual General Meeting in 2020, for the purpose of issuing
shares under the Company's restricted stock unit (RSU) program to its board
members. The shares are issued at a price of NOK 20.804 per share, which equals
the market price of the share in the last private placement of the Company.
Following the share capital increase, the Company will have a share capital of
NOK 119,968.668 divided into 29,992,167 shares, each with a nominal value of NOK
This information is subject to the disclosure requirements pursuant to Section
5-12 of the Norwegian Securities Trading Act.
EXACT-Tx is a clinical stage Norwegian biotech company developing a technology
platform for targeted therapeutic enhancement - Acoustic Cluster Therapy (ACT®).
ACT® sonoporation is a unique approach to ultrasound-mediated, targeted drug
enhancement - with the potential to significantly amplify the clinical utility
of a wide range of therapeutic agents across a multitude of indications
including within oncology (chemotherapy, immunotherapy), infectious diseases,
and neurological conditions. www.exact-tx.com